MYRIAD GENETICS INCMYGNEarnings & Financial Report
Myriad Genetics, Inc. is an American genetic testing and precision medicine company based in Salt Lake City, Utah, United States. Myriad employs a number of proprietary technologies that permit doctors and patients to understand the genetic basis of human disease and the role that genes play in the onset, progression and treatment of disease. This information is used to guide the development of new products that assess an individual's risk for developing disease later in life, identify a pati...
MYGN Q4 FY2025 Key Financial Metrics
Revenue
$209.8M
Gross Profit
$146.8M
Operating Profit
$-5.7M
Net Profit
N/A
Gross Margin
70.0%
Operating Margin
-2.7%
Net Margin
N/A
YoY Growth
-0.4%
EPS
$-0.09
MYRIAD GENETICS INC Q4 FY2025 Financial Summary
MYRIAD GENETICS INC reported revenue of $209.8M (down 0.4% YoY) for Q4 FY2025, with a net profit of N/A (N/A margin). Cost of goods sold was $63.0M, operating expenses totaled $152.5M.
Key Financial Metrics
| Total Revenue | $209.8M |
|---|---|
| Net Profit | N/A |
| Gross Margin | 70.0% |
| Operating Margin | -2.7% |
| Report Period | Q4 FY2025 |
MYRIAD GENETICS INC Annual Revenue by Year
MYRIAD GENETICS INC annual revenue history includes year-by-year totals (for example, 2025 revenue was $824.5M).
MYRIAD GENETICS INC Quarterly Revenue & Net Profit History
MYRIAD GENETICS INC results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $209.8M | -0.4% | N/A | N/A |
| Q3 FY2025 | $205.7M | -3.6% | $-27.4M | -13.3% |
| Q2 FY2025 | $213.1M | +0.8% | $-330.5M | -155.1% |
| Q1 FY2025 | $195.9M | -3.1% | $-100.0K | -0.1% |
| Q4 FY2024 | $210.6M | +7.1% | N/A | N/A |
| Q3 FY2024 | $213.3M | +11.2% | $-22.1M | -10.4% |
| Q2 FY2024 | $211.5M | +15.3% | $-36.7M | -17.4% |
| Q1 FY2024 | $202.2M | +11.6% | $-26.0M | -12.9% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $202.2M | $211.5M | $213.3M | $210.6M | $195.9M | $213.1M | $205.7M | $209.8M |
| YoY Growth | 11.6% | 15.3% | 11.2% | 7.1% | -3.1% | 0.8% | -3.6% | -0.4% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $1.11B | $1.09B | $1.08B | $1.03B | $1.01B | $677.3M | $728.1M | $706.6M |
| Liabilities | $350.5M | $344.6M | $349.6M | $326.5M | $301.2M | $289.2M | $355.3M | $338.6M |
| Equity | $760.0M | $740.5M | $731.7M | $701.1M | $704.9M | $388.1M | $372.8M | $368.0M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-18.6M | $2.6M | $700000 | $6.6M | $-16.3M | $-13.6M | $21.1M | $10.6M |